


## DG172 dihydrochloride

<b>Cat. No.:</b>	HY-19737A
<b>CAS No.:</b>	1361504-77-9
<b>Molecular Formula:</b>	C <sub>20</sub> H <sub>22</sub> BrCl <sub>2</sub> N <sub>3</sub>
<b>Molecular Weight:</b>	455.22
<b>Target:</b>	PPAR
<b>Pathway:</b>	Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor
<b>Storage:</b>	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



### SOLVENT & SOLUBILITY

#### In Vitro

H<sub>2</sub>O : 14.29 mg/mL (31.39 mM; Need ultrasonic)

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	2.1967 mL	10.9837 mL	21.9674 mL
	5 mM	0.4393 mL	2.1967 mL	4.3935 mL
	10 mM	0.2197 mL	1.0984 mL	2.1967 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

<b>Description</b>	DG172 dihydrochloride is a selective PPARβ/δ antagonist, with an IC <sub>50</sub> of 27 nM.
<b>IC<sub>50</sub> &amp; Target</b>	PPARβ/δ 27 nM (IC <sub>50</sub> )
<b>In Vitro</b>	DG172 dihydrochloride is a selective PPARβ/δ antagonist, with an IC <sub>50</sub> of 27 nM. DG172 enhances transcriptional corepressor recruitment, and down-regulates transcription of the PPARβ/δ target gene Angptl4 in mouse myoblasts (IC <sub>50</sub> , 9.5 nM) <sup>[1]</sup> . DG172 (1 μM) promotes the differentiation of dendritic cells (DCs) from GM-CSF-induced mouse bone marrow cells (BMCs) and reduces Ly6b <sup>+</sup> /Gr1 <sup>+</sup> granulocytic cells. DG172 has effects on the transcriptome of GM-CSF differentiated BMCs from WT and Ppard null mice, and acts at a specific stage of GM-CSF-induced differentiation <sup>[2]</sup> . DG172 (0.1, 1.0 μM) dose-dependently promotes proliferation of TM4 cells. DG172 reduces expression of claudin-11 in TM4 cells <sup>[3]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### PROTOCOL

---

**Cell Assay** <sup>[3]</sup>

The xCELLigence system is used for determining the changes in real time cell proliferation in response to activation of PPAR $\delta$  with an agonist (GW0742) or an inverse agonist (DG172) or the effect of inhibiting ERK signaling in TM4 cells<sup>[3]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

---

**REFERENCES**

- [1]. Lieber S, et al. (Z)-2-(2-bromophenyl)-3-[[4-(1-methyl-piperazine)amino]phenyl]acrylonitrile (DG172): an orally bioavailable PPAR $\beta/\delta$ -selective ligand with inverse agonistic properties. *J Med Chem*. 2012 Mar 22;55(6):2858-68.
- [2]. Lieber S, et al. The inverse agonist DG172 triggers a PPAR $\beta/\delta$ -independent myeloid lineage shift and promotes GM-CSF/IL-4-induced dendritic cell differentiation. *Mol Pharmacol*. 2015 Feb;87(2):162-73.
- [3]. Yao PL, et al. Peroxisome Proliferator-activated Receptor-D (PPAR $\delta$ ) Coordinates Mouse Spermatogenesis by Modulating Extracellular Signal-regulated Kinase (ERK)-dependent Signaling. *J Biol Chem*. 2015 Sep 18;290(38):23416-31.
- 

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA